Quarterly report · Q1
2503.TEDINET S100TE18
Period2024-01-01 → 2024-03-31
Filed2024-05-13
StandardIFRS
ConsolidatedYes
Data checks12 of 12 passed
Key figures · 47
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥501.8bn | 2024-01-01 → 2024-03-31 | Cons. | Revenue IFRS |
| Revenue | ¥2.13T | 2023-01-01 → 2023-12-31 | Cons. | Revenue IFRS (5-year summary) |
| Revenue | ¥450.3bn | 2023-01-01 → 2023-03-31 | Cons. | Revenue IFRS |
| Operating income | ¥30.8bn | 2024-01-01 → 2024-03-31 | Cons. | Operating profit loss IFRS |
| Operating income | ¥11.0bn | 2023-01-01 → 2023-03-31 | Cons. | Operating profit loss IFRS |
| Profit before tax | ¥44.2bn | 2024-01-01 → 2024-03-31 | Cons. | Profit loss before tax IFRS |
| Profit before tax | ¥197.0bn | 2023-01-01 → 2023-12-31 | Cons. | Profit loss before tax IFRS (5-year summary) |
| Profit before tax | ¥20.1bn | 2023-01-01 → 2023-03-31 | Cons. | Profit loss before tax IFRS |
| Net income (owners) | ¥25.9bn | 2024-01-01 → 2024-03-31 | Cons. | Profit loss attributable to owners of parent IFRS |
| Net income (owners) | ¥112.7bn | 2023-01-01 → 2023-12-31 | Cons. | Profit loss attributable to owners of parent IFRS (5-year summary) |
| Net income (owners) | ¥5.6bn | 2023-01-01 → 2023-03-31 | Cons. | Profit loss attributable to owners of parent IFRS |
| Net income | ¥32.6bn | 2024-01-01 → 2024-03-31 | Cons. | Profit loss IFRS |
| Net income | ¥11.3bn | 2023-01-01 → 2023-03-31 | Cons. | Profit loss IFRS |
| Total assets | ¥3.00T | at 2024-03-31 | Cons. | Assets IFRS |
| Total assets | ¥2.87T | at 2023-12-31 | Cons. | Assets IFRS |
| Total assets | ¥2.47T | at 2023-03-31 | Cons. | Total assets IFRS (5-year summary) |
| Total liabilities | ¥1.55T | at 2024-03-31 | Cons. | Liabilities IFRS |
| Total liabilities | ¥1.44T | at 2023-12-31 | Cons. | Liabilities IFRS |
| Net assets / equity | ¥1.46T | at 2024-03-31 | Cons. | Equity IFRS |
| Net assets / equity | ¥1.43T | at 2023-12-31 | Cons. | Equity IFRS |
| Net assets / equity | ¥1.23T | at 2023-03-31 | Cons. | Equity IFRS |
| Net assets / equity | ¥1.25T | at 2022-12-31d | Cons. | Equity IFRS |
| Equity (owners) | ¥1.16T | at 2024-03-31 | Cons. | Equity attributable to owners of parent IFRS |
| Equity (owners) | ¥1.13T | at 2023-12-31 | Cons. | Equity attributable to owners of parent IFRS |
| Equity (owners) | ¥971.9bn | at 2023-03-31 | Cons. | Equity attributable to owners of parent IFRS (5-year summary) |
| Cash & equivalents | ¥151.2bn | at 2024-03-31 | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥131.4bn | at 2023-12-31 | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥116.9bn | at 2023-03-31 | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥88.1bn | at 2022-12-31d | Cons. | Cash and cash equivalents IFRS |
| Operating cash flow | ¥39.9bn | 2024-01-01 → 2024-03-31 | Cons. | Net cash provided by used in operating activities IFRS |
| Operating cash flow | ¥203.2bn | 2023-01-01 → 2023-12-31 | Cons. | Cash flows from used in operating activities IFRS (5-year summary) |
| Operating cash flow | ¥41.9bn | 2023-01-01 → 2023-03-31 | Cons. | Net cash provided by used in operating activities IFRS |
| Investing cash flow | −¥65.3bn | 2024-01-01 → 2024-03-31 | Cons. | Net cash provided by used in investing activities IFRS |
| Investing cash flow | −¥226.1bn | 2023-01-01 → 2023-12-31 | Cons. | Cash flows from used in investing activities IFRS (5-year summary) |
| Investing cash flow | −¥31.4bn | 2023-01-01 → 2023-03-31 | Cons. | Net cash provided by used in investing activities IFRS |
| Financing cash flow | ¥34.7bn | 2024-01-01 → 2024-03-31 | Cons. | Net cash provided by used in financing activities IFRS |
| Financing cash flow | ¥35.9bn | 2023-01-01 → 2023-12-31 | Cons. | Cash flows from used in financing activities IFRS (5-year summary) |
| Financing cash flow | −¥8.6bn | 2023-01-01 → 2023-03-31 | Cons. | Net cash provided by used in financing activities IFRS |
| EPS (basic) | ¥31.98 | 2024-01-01 → 2024-03-31 | Cons. | Basic earnings loss per share IFRS |
| EPS (basic) | ¥139.16 | 2023-01-01 → 2023-12-31 | Cons. | Basic earnings loss per share IFRS (5-year summary) |
| EPS (basic) | ¥6.9 | 2023-01-01 → 2023-03-31 | Cons. | Basic earnings loss per share IFRS |
| EPS (diluted) | ¥31.98 | 2024-01-01 → 2024-03-31 | Cons. | Diluted earnings loss per share IFRS |
| EPS (diluted) | ¥139.15 | 2023-01-01 → 2023-12-31 | Cons. | Diluted earnings loss per share IFRS (5-year summary) |
| EPS (diluted) | ¥6.9 | 2023-01-01 → 2023-03-31 | Cons. | Diluted earnings loss per share IFRS |
| Equity ratio | 38.7% | at 2024-03-31 | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| Equity ratio | 39.5% | at 2023-12-31 | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| Equity ratio | 39.4% | at 2023-03-31 | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 46
| Segment | Item | Period | Value |
|---|---|---|---|
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue | 2024-01-01 → 2024-03-31 | ¥20.0bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue external | 2024-01-01 → 2024-03-31 | ¥4.6bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue intersegment | 2024-01-01 → 2024-03-31 | ¥15.3bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment profit | 2024-01-01 → 2024-03-31 | −¥158m |
| Reconciling Itemsreconciling | revenue | 2024-01-01 → 2024-03-31 | −¥17.2bn |
| Reconciling Itemsreconciling | revenue intersegment | 2024-01-01 → 2024-03-31 | −¥17.2bn |
| Reconciling Itemsreconciling | segment profit | 2024-01-01 → 2024-03-31 | −¥12.3bn |
| jpcrp040300-q1r_E00395-000Alcoholic Beveragesreportable segment | revenue | 2024-01-01 → 2024-03-31 | ¥238.6bn |
| jpcrp040300-q1r_E00395-000Alcoholic Beveragesreportable segment | revenue external | 2024-01-01 → 2024-03-31 | ¥238.2bn |
| jpcrp040300-q1r_E00395-000Alcoholic Beveragesreportable segment | revenue intersegment | 2024-01-01 → 2024-03-31 | ¥379m |
| jpcrp040300-q1r_E00395-000Alcoholic Beveragesreportable segment | segment profit | 2024-01-01 → 2024-03-31 | ¥18.4bn |
| jpcrp040300-q1r_E00395-000Health Sciencereportable segment | revenue | 2024-01-01 → 2024-03-31 | ¥32.7bn |
| jpcrp040300-q1r_E00395-000Health Sciencereportable segment | revenue external | 2024-01-01 → 2024-03-31 | ¥31.9bn |
| jpcrp040300-q1r_E00395-000Health Sciencereportable segment | revenue intersegment | 2024-01-01 → 2024-03-31 | ¥726m |
| jpcrp040300-q1r_E00395-000Health Sciencereportable segment | segment profit | 2024-01-01 → 2024-03-31 | −¥1.7bn |
| jpcrp040300-q1r_E00395-000Non Alcoholic Beveragesreportable segment | revenue | 2024-01-01 → 2024-03-31 | ¥122.2bn |
| jpcrp040300-q1r_E00395-000Non Alcoholic Beveragesreportable segment | revenue external | 2024-01-01 → 2024-03-31 | ¥121.5bn |
| jpcrp040300-q1r_E00395-000Non Alcoholic Beveragesreportable segment | revenue intersegment | 2024-01-01 → 2024-03-31 | ¥645m |
| jpcrp040300-q1r_E00395-000Non Alcoholic Beveragesreportable segment | segment profit | 2024-01-01 → 2024-03-31 | ¥12.2bn |
| jpcrp040300-q1r_E00395-000Pharmaceuticalsreportable segment | revenue | 2024-01-01 → 2024-03-31 | ¥105.6bn |
| jpcrp040300-q1r_E00395-000Pharmaceuticalsreportable segment | revenue external | 2024-01-01 → 2024-03-31 | ¥105.5bn |
| jpcrp040300-q1r_E00395-000Pharmaceuticalsreportable segment | revenue intersegment | 2024-01-01 → 2024-03-31 | ¥67m |
| jpcrp040300-q1r_E00395-000Pharmaceuticalsreportable segment | segment profit | 2024-01-01 → 2024-03-31 | ¥16.5bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue | 2023-01-01 → 2023-03-31 | ¥22.3bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue external | 2023-01-01 → 2023-03-31 | ¥6.4bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue intersegment | 2023-01-01 → 2023-03-31 | ¥16.0bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment profit | 2023-01-01 → 2023-03-31 | −¥265m |
| Reconciling Itemsreconciling | revenue | 2023-01-01 → 2023-03-31 | −¥18.0bn |
| Reconciling Itemsreconciling | revenue intersegment | 2023-01-01 → 2023-03-31 | −¥18.0bn |
| Reconciling Itemsreconciling | segment profit | 2023-01-01 → 2023-03-31 | −¥11.5bn |
| jpcrp040300-q1r_E00395-000Alcoholic Beveragesreportable segment | revenue | 2023-01-01 → 2023-03-31 | ¥225.4bn |
| jpcrp040300-q1r_E00395-000Alcoholic Beveragesreportable segment | revenue external | 2023-01-01 → 2023-03-31 | ¥225.1bn |
| jpcrp040300-q1r_E00395-000Alcoholic Beveragesreportable segment | revenue intersegment | 2023-01-01 → 2023-03-31 | ¥300m |
| jpcrp040300-q1r_E00395-000Alcoholic Beveragesreportable segment | segment profit | 2023-01-01 → 2023-03-31 | ¥20.9bn |
| jpcrp040300-q1r_E00395-000Health Sciencereportable segment | revenue | 2023-01-01 → 2023-03-31 | ¥18.4bn |
| jpcrp040300-q1r_E00395-000Health Sciencereportable segment | revenue external | 2023-01-01 → 2023-03-31 | ¥17.4bn |
| jpcrp040300-q1r_E00395-000Health Sciencereportable segment | revenue intersegment | 2023-01-01 → 2023-03-31 | ¥991m |
| jpcrp040300-q1r_E00395-000Health Sciencereportable segment | segment profit | 2023-01-01 → 2023-03-31 | −¥1.4bn |
| jpcrp040300-q1r_E00395-000Non Alcoholic Beveragesreportable segment | revenue | 2023-01-01 → 2023-03-31 | ¥108.6bn |
| jpcrp040300-q1r_E00395-000Non Alcoholic Beveragesreportable segment | revenue external | 2023-01-01 → 2023-03-31 | ¥108.0bn |
| jpcrp040300-q1r_E00395-000Non Alcoholic Beveragesreportable segment | revenue intersegment | 2023-01-01 → 2023-03-31 | ¥609m |
| jpcrp040300-q1r_E00395-000Non Alcoholic Beveragesreportable segment | segment profit | 2023-01-01 → 2023-03-31 | ¥9.6bn |
| jpcrp040300-q1r_E00395-000Pharmaceuticalsreportable segment | revenue | 2023-01-01 → 2023-03-31 | ¥93.5bn |
| jpcrp040300-q1r_E00395-000Pharmaceuticalsreportable segment | revenue external | 2023-01-01 → 2023-03-31 | ¥93.4bn |
| jpcrp040300-q1r_E00395-000Pharmaceuticalsreportable segment | revenue intersegment | 2023-01-01 → 2023-03-31 | ¥107m |
| jpcrp040300-q1r_E00395-000Pharmaceuticalsreportable segment | segment profit | 2023-01-01 → 2023-03-31 | ¥16.2bn |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 779
| Item | Context | Value | Unit |
|---|---|---|---|
| Treasury shares etc (text) | FilingDateInstant | Text · Plus | |
| Name of shareholder treasury shares etc | CurrentQuarterInstant_Row1Member | Original text (Japanese)キリンホールディングス株式会社 | |
| Address of shareholder treasury shares etc | CurrentQuarterInstant_Row1Member | Original text (Japanese)東京都中野区中野四丁目10番２号 | |
| Information about officers (text) | FilingDateInstant | Text · Plus | |
| Description of fact that consolidated financial statements have been prepared in accordance with IFRS financial information | CurrentYTDDuration | Text · Plus | |
| Note on independent audit financial information | CurrentYTDDuration | Text · Plus | |
| Condensed quarterly consolidated statement of financial position IFRS (text) | CurrentYTDDuration | Text · Plus | |
| Condensed year to quarter end consolidated statement of profit or loss IFRS (text) | CurrentYTDDuration | Text · Plus | |
| Condensed year to quarter end consolidated statement of comprehensive income IFRS (text) | CurrentYTDDuration | Text · Plus | |
| Condensed quarterly consolidated statement of changes in equity IFRS (text) | CurrentYTDDuration | Text · Plus | |
| Condensed quarterly consolidated statement of cash flows IFRS (text) | CurrentYTDDuration | Text · Plus | |
| Notes reporting entity condensed quarterly consolidated financial statements IFRS (text) | CurrentYTDDuration | Text · Plus | |
| Notes basis of preparation condensed quarterly consolidated financial statements IFRS (text) | CurrentYTDDuration | Text · Plus | |
| Notes significant accounting policies condensed quarterly consolidated financial statements IFRS (text) | CurrentYTDDuration | Text · Plus | |
| Notes segment information condensed quarterly consolidated financial statements IFRS (text) | CurrentYTDDuration | Text · Plus | |
| Disclosure of changes in reportable segments IFRS (text) | CurrentYTDDuration | Text · Plus | |
| Notes equity condensed quarterly consolidated financial statements IFRS (text) | CurrentYTDDuration | Text · Plus | |
| Notes revenue condensed quarterly consolidated financial statements IFRS (text) | CurrentYTDDuration | Text · Plus | |
| Notes selling general and administrative expenses condensed quarterly consolidated financial statements IFRS (text) | CurrentYTDDuration | Text · Plus | |
| Notes other operating income condensed quarterly consolidated financial statements IFRS (text) | CurrentYTDDuration | Text · Plus | |
| Notes other operating expenses condensed quarterly consolidated financial statements IFRS (text) | CurrentYTDDuration | Text · Plus | |
| Notes finance income and finance costs condensed quarterly consolidated financial statements IFRS (text) | CurrentYTDDuration | Text · Plus | |
| Notes cash flow information condensed quarterly consolidated financial statements IFRS (text) | CurrentYTDDuration | Text · Plus | |
| Notes earnings per share condensed quarterly consolidated financial statements IFRS (text) | CurrentYTDDuration | Text · Plus | |
| Notes financial instruments condensed quarterly consolidated financial statements IFRS (text) | CurrentYTDDuration | Text · Plus | |
| Notes business combinations condensed quarterly consolidated financial statements IFRS (text) | CurrentYTDDuration | Text · Plus | |
| Notes subsequent events condensed quarterly consolidated financial statements IFRS (text) | CurrentYTDDuration | Text · Plus | |
| Other information consolidated financial statements etc (text) | CurrentYTDDuration | Text · Plus | |
| Information about company which provides guarantee to reporting company (text) | FilingDateInstant | Text · Plus |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 12 of 12 passed
| balance sheet identity | pass |
| balance sheet identity | pass |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |